Dr. Brian Henick: Columbia University Irving Cancer Center

Quick Facts

Primary Location:
New York-Presbyterian Hospital/Columbia University Medical Center
Expertise:
Thoracic Cancer
Immunotherapy
Speciality:
Hematology
Gender:
Male
Language:
English
Med School:
Rutgers New Jersey Medical School

Get to Know Dr. Brian Henick

Medical oncologist Dr. Brian Henick specializes in thoracic malignancies, including lung cancer and mesothelioma, and in personalizing patient care through novel therapeutics.

Henick believes in a multidisciplinary approach to treatment that includes the computational study of cancer immunobiology, the latest advancement in cancer care.

With every patient he serves, his goal is improving the current treatment strategy by maximizing the vast resources of one of the country’s leading cancer centers and its mesothelioma doctors.

Learn More About Mesothelioma Treatment

The National Cancer Institute has recognized the Columbia University Herbert Irving Comprehensive Cancer Center as an elite Comprehensive Cancer Center for more than 30 years.

Henick takes pride in staying attuned to the values and needs of each individual. His areas of treatment expertise include esophageal cancer and thymoma through the field of hematology.

He also serves as an associate professor of medicine at the Columbia University Irving Medical Center.

Contact Dr. Brian Henick

212-305-5098

Specialties of Dr. Brian Henick

Immunotherapy
Lung cancer
Pleural mesothelioma
Esophageal cancer
Hematology
Oncology
Thoracic cancers

Dr. Brian Henick’s Experience and Medical Education

Columbia University Herbert Irving Comprehensive Cancer Center
Rutgers New Jersey Medical School (M.D.)
Yale New Haven Hospital (Fellowship, residency, internship)

Awards and Other Recognitions

ASCO Journals Editorial Fellowship
Conquer Cancer/ASCO Foundation Merit Award
Conquer Cancer/ASCO Young Investigator Award
Society for Immunotherapy of Cancer Sparkathon
Gold Humanism Honor Society

Publications of Dr. Brian Henick

Henick, B. (2020, February 11). Elite Intratumoral T-cell Clonotypes (The 1%) Effect “Trickle-Down Cytotoxicity.” Clinical Cancer Research.
Zugazagoitia, J. et al. (2019, October 9). Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. Journal of Thoracic Oncology.
Henick, B. et al. (2014, December 18). The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Thoracic Targets.